On September 4, 2024, the innovative formulation team led by Professor Liu Xiangrui from the Future Health Laboratory of the Yangtze River Delta Smart Oasis Innovation Center at Zhejiang University, in collaboration with China Resources Zizhu Pharmaceutical, obtained clinical implied permission from the National Medical Products Administration (CDE) to conduct clinical research on the 2.2 class new drug ZP036.

ZP036 is used to treat functional disorders caused by progesterone deficiency, including menstrual disorders caused by ovulation dysfunction, dysmenorrhea and premenstrual syndrome, bleeding (caused by fibroids, etc.), premenopausal disorders, menopause (used for estrogen supplementation therapy), and also helps with pregnancy. ZP036 is an improved new drug that has not been marketed domestically or internationally, with independent intellectual property rights, and is expected to break the current market dominance of imported drugs in this category. Wei Mengying, a specially appointed researcher in the innovative formulation team of the Smart Oasis Innovation Center, and Lin Yuanyuan, an engineering specialist, participated in the research and development of this new drug.

Team Introduction:

The innovative formulation team is led by Professor Liu Xiangrui and consists of more than ten young research backbones, focusing on the application and transformation research of innovative drug formulations, oral dietary supplements, and pharmaceutical excipients. At present, the team has established joint research institutions with multiple companies such as China Resources Sanjiu Pharmaceutical Co., Ltd. and Shanghai Xiaoya Biotechnology Co., Ltd. Through systematic measures of interconnectivity and complementarity, the team and enterprises work together to tackle challenges, striving to efficiently and quickly transform scientific research achievements into pharmaceutical products that serve the public.